{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:30:01Z","timestamp":1782873001683,"version":"3.54.5"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>Tobacco addiction is the primary preventable factor contributing to global mortality, and nicotine is one of the substances with the greatest potential for addiction. With a strong affinity for the \u03b14\u03b22 subtype receptor, cytisine (CYT) functions as a partial agonist of the acetylcholine nicotinic cholinergic receptor. It counteracts the effects of nicotine without causing any withdrawal symptoms. These features, combined with its limited mild adverse effects and minimal drug\u2013drug interactions, make cytisine a cost-effective treatment for smoking cessation. The current protocol describes a prospective observational study on the safety and efficacy of CYT administered to inpatient smokers of the Integrated University Hospital of Verona (IUHVR), Veneto (Italy). This is a monocentric, observational, and prospective study on both sex smokers over the age of 18\u2009years admitted to the IUHVR who meet the criteria for recruitment and have given their consent. Eligible participants will be assigned to the CYT intervention based on the West dosing schedule and will be followed up for 12\u2009months from treatment initiation. Evaluation of safety, efficacy, and compliance will be assessed at 7 and 25\u2009days, with follow-up at 3, 6, and 12\u2009months from the start of the treatment (quit day). During each visit, any adverse events or adverse reactions reported by patients following the intake of CYT will be evaluated. This study will contribute, for the first time, to the knowledge about the use of CYT for smoking cessation in a hospital setting.<\/jats:p>","DOI":"10.3389\/fpubh.2024.1350176","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T04:44:54Z","timestamp":1727671494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of CyTisine for smoking cessation in a hOSPital context (CITOSP): study protocol for a prospective observational study"],"prefix":"10.3389","volume":"12","author":[{"given":"Alessandro","family":"Torazzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Tedesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Ceccato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Santin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Campagnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Losso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Toldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Casari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Arzenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Chiamulera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Lugoboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"ref1","volume-title":"World Health Organization","year":"2023"},{"key":"ref2","first-page":"e35086","article-title":"Pharmacotherapy in tobacco cessation: a narrative review","author":"Pajai","year":"2023"},{"key":"ref3","year":"2023"},{"key":"ref4","volume-title":"WHO report on the global tobacco epidemic: monitoring tobacco use and prevention policies","year":"2017"},{"key":"ref5","first-page":"3","article-title":"Addiction to tobacco smoking and vaping","volume-title":"Rev Invest Clin","author":"Hern\u00e1ndez-p\u00e9rez","year":"2023"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009329.pub2","article-title":"Pharmacological interventions for smoking cessation: an overview and network meta-analysis","volume":"2015","author":"Cahill","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1102035","article-title":"Placebo-controlled trial of cytisine for smoking cessation","volume":"365","author":"West","year":"2011","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006103.pub7","article-title":"Nicotine receptor partial agonists for smoking cessation","volume":"2016","author":"Cahill","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/archinte.166.15.1553","article-title":"Cytisine for smoking cessation: a literature review and a meta-analysis","volume":"166","author":"Etter","year":"2006","journal-title":"Arch Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/jps.2600650309","article-title":"Structure and toxicity of alkaloids and amino acids of Sophora secundiflora","volume":"65","author":"Izaddoost","year":"1976","journal-title":"J Pharm Sci"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1021\/ja01190a077","article-title":"The papilionaceous alkaloids; Baptisia minor, Lehm","volume":"70","author":"Marion","year":"1948","journal-title":"J Am Chem Soc"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1021\/cr400307e","article-title":"(\u2212)-Cytisine and derivatives: synthesis, reactivity, and applications","volume":"114","author":"Rouden","year":"2014","journal-title":"Chem Rev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1007\/s10600-012-0268-3","article-title":"Synthesis of N-(2-aminoethyl)- and N-(3-aminopropyl)cytisine","volume":"48","author":"Shishkin","year":"2012","journal-title":"Chem Nat Compd"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1360-0443.2007.02083.x","article-title":"Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness","volume":"103","author":"Stapleton","year":"2008","journal-title":"Addiction"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.tips.2007.05.003","article-title":"Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation","volume":"28","author":"Rollema","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/jnc.12721","article-title":"\u03b16\u03b22*-subtype nicotinic acetylcholine receptors are more sensitive than \u03b14\u03b22*-subtype receptors to regulation by chronic nicotine administration","volume":"130","author":"Marks","year":"2014","journal-title":"J Neurochem"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.pbb.2008.08.024","article-title":"Effects of the nicotinic receptor partial agonists varenicline and cytisine on the discriminative stimulus effects of nicotine in rats","volume":"91","author":"LeSage","year":"2009","journal-title":"Pharmacol Biochem Behav"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1111\/add.14721","article-title":"Cytisine for nicotine addiction treatment: a review of pharmacology, therapeutics and an update of clinical trial evidence for smoking cessation","volume":"114","author":"Tutka","year":"2019","journal-title":"Addiction"},{"key":"ref19","first-page":"777","volume-title":"Pharmacol Rep","author":"Tutka","year":"2006"},{"key":"ref20","first-page":"2092","author":"Bennodorf","year":"1968"},{"key":"ref21","author":"Stoyanov","year":"1965"},{"key":"ref22","author":"Bennodorf","year":"1970"},{"key":"ref23","author":"Maliszewski","year":"1972"},{"key":"ref24","volume-title":"Pharmacokinetics and metabolism of nicotinePharmacol Rep","author":"Tutka","year":"2005"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2478\/v10102-010-0003-5","article-title":"Pharmacokinetics of cytisine after single intravenous and oral administration in rabbits","volume":"3","author":"Astroug","year":"2010","journal-title":"Interdiscip Toxicol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/978-3-642-67729-8_63","article-title":"Pharmacokinetic studies with 3H-cytisine","volume":"4","author":"Kl\u00f6cking","year":"1980","journal-title":"Arch Toxicol Suppl"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/dta.1707","article-title":"Pharmacokinetics of cytisine, an \u03b14 \u03b22 nicotinic receptor partial agonist, in healthy smokers following a single dose","volume":"7","author":"Jeong","year":"2015","journal-title":"Drug Test Anal"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1136\/thoraxjnl-2012-203035","article-title":"Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis","volume":"68","author":"Hajek","year":"2013","journal-title":"Thorax"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1056\/NEJMoa1407764","article-title":"Cytisine versus nicotine for smoking cessation","volume":"371","author":"Walker","year":"2014","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0306-4603(03)00084-4","article-title":"A comparison of four self-report smoking cessation outcome measures","volume":"29","author":"Velicer","year":"2004","journal-title":"Addictive Behaviors"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-017-4902-7","article-title":"Exploring consensus on how to measure smoking cessation. A Delphi study","volume":"17","author":"Cheung","year":"2017","journal-title":"BMC Public Health"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/14622200210123581","article-title":"Biochemical verification of tobacco use and cessation","volume":"4","year":"2002","journal-title":"Nicotine Tob Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1378\/chest.117.3.758","article-title":"Breath carbon monoxide as an indication of smoking habit","volume":"117","author":"Middleton","year":"2000","journal-title":"Chest"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medicina56070320","article-title":"Pharmacological interactions in the elderly","volume":"56","author":"B\u0142eszy\u0144ska","year":"2020","journal-title":"Medicina"},{"key":"ref35","volume-title":"CHAMPIX (varenicline) - Lots to be recalled due to presence of impurity N-nitroso-varenicline above the Pfizer acceptable daily intake limit","year":"2021"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1350176\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T04:44:56Z","timestamp":1727671496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2024.1350176\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":35,"alternative-id":["10.3389\/fpubh.2024.1350176"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2024.1350176","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"article-number":"1350176"}}